Effect of aspirin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from randomized controlled trials and real-world studies

Ma, Shaodi; Xia, Weihang; Wu, Birong; Sun, Chenyu; Jiang, Yuemeng; Liu, Haixia; Lowe, Scott; Zhou, Zhen; Xie, Peng; Gao, Juan; Feng, Linya; Guo, Xianwei; Qu, Guangbo; Sun, Yehuan

doi:10.1007/s00228-023-03556-7

Cited by 2 publications

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The potential causal association between aspirin consumption and the risk of prostate cancer incidence: a Mendelian randomization analysis

Zhu,

Lai,

Lai

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Currently, the potential link between aspirin use and the development of prostate cancer remains uncertain. The purpose of this study using two-sample Mendelian randomization (MR) was to elucidate the causal effect of aspirin use on prostate cancer (PCa) risk. Methods This study included pooled statistics from two Genome-Wide Association Study (GWAS), one for aspirin use (61583 cases and 50427 control) and the other for PCa of European descent (22534 cases and 270176 control). Inverse variance weighting (IVW) was used as the main method, MR-Egger method, weighted median method and weighted model method were used to evaluate the causal relationship between aspirin use and PCa risk. Cochran's Q test was used to check the heterogeneity, and the MR-Egger intercept test was used to analyze the horizontal pleotropy of the results, and a residual analysis was carried out to confirm the robustness and reliability of the results. Results Inverse variance weighting was used to infer that aspirin use had a protective effect on reducing the incidence of PCa (OR = 0.986, 95% CI = 0.978–0.994, P = 0.001). Sensitivity analysis showed that pleiotropy and heterogeneity were not observed. Furthermore, the remain-one analysis showed that the survey results were not significantly affected by any instrumental variable. Conclusion There is a causal relationship between aspirin use and the development of PCa, that is, aspirin use reduces the risk of PCa.

show abstract

The potential causal association between aspirin consumption and the risk of prostate cancer incidence: a Mendelian randomization analysis

Zhu,

Lai,

Lai

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Exploring Aspirin’s Potential in Cancer Prevention: A Comprehensive Review of the Current Evidence

Miret Durazo,

Zachariah Saji,

Rawat

et al. 2024

Cureus

View full text Add to dashboard Cite

Aspirin, traditionally recognized for its analgesic, anti-inflammatory, antipyretic, and antiplatelet effects, has recently attracted attention for its potential role in cancer prevention. Initially studied for cardiovascular disease prevention, emerging evidence suggests that aspirin may reduce the risk of certain cancers, particularly colorectal cancer (CRC). This narrative review integrates findings from early studies, animal models, epidemiological data, and clinical trials to evaluate aspirin's efficacy as a chemopreventive agent. Aspirin’s anticancer effects are primarily attributed to its cyclooxygenase (COX) enzyme inhibition, which decreases prostaglandin E2 (PGE2) levels and disrupts cancer-related signaling pathways. While epidemiological studies support an association between aspirin use and reduced cancer incidence and mortality, especially for CRC and potentially for breast (BC) and prostate cancers (PCa), the risk of adverse effects, such as gastrointestinal (GI) and intracranial bleeding, complicates its use and warrants careful consideration. The decision to use aspirin for cancer prevention should be individualized, balancing its therapeutic benefits against potential adverse effects. It also underscores the necessity for further research to refine dosage guidelines, assess long-term impacts, and explore additional biomarkers to guide personalized cancer prevention strategies.

show abstract

Effect of aspirin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from randomized controlled trials and real-world studies

Cited by 2 publications

References 108 publications

The potential causal association between aspirin consumption and the risk of prostate cancer incidence: a Mendelian randomization analysis

The potential causal association between aspirin consumption and the risk of prostate cancer incidence: a Mendelian randomization analysis

Exploring Aspirin’s Potential in Cancer Prevention: A Comprehensive Review of the Current Evidence

Contact Info

Product

Resources

About